About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: AZN
- Previous Close: $57.25
- 50 Day Moving Average: $4464.19
- 200 Day Moving Average: $4650.98
- 52-Week Range: £12,650,000 - GBX 3,680
- Trailing P/E Ratio: 16.56
- P/E Growth: 4.20
- Market Cap: $57.81B
- Outstanding Shares: 1,265,000,000
Consensus Ratings for AstraZeneca plc (LON:AZN) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||4 Sell Ratings, 9 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||GBX 4,953.82|
Analysts' Ratings History for AstraZeneca plc (LON:AZN)
(Data available from 2/20/2015 forward)
|2/20/2017||Beaufort Securities||Reiterated Rating||Hold|
|2/20/2017||J P Morgan Chase & Co||Reiterated Rating||Neutral|
|2/17/2017||Goldman Sachs Group, Inc. (The)||Set Price Target||Sell||GBX 3,900|
|2/17/2017||Jefferies Group LLC||Boost Price Target||Buy||GBX 4,800 -> GBX 5,250|
|2/16/2017||Shore Capital||Reiterated Rating||Sell||GBX 4,595|
|2/13/2017||Liberum Capital||Lower Price Target||Buy||GBX 5,200 -> GBX 5,100|
|2/8/2017||BNP Paribas||Reiterated Rating||Neutral||GBX 5,300|
|2/7/2017||HSBC Holdings plc||Lower Price Target||Hold||GBX 4,700 -> GBX 4,500|
|2/6/2017||Deutsche Bank AG||Lower Price Target||Buy||GBX 6,000 -> GBX 5,500|
|2/3/2017||Credit Suisse Group||Reiterated Rating||Underperform||GBX 4,000|
|1/23/2017||Investec||Initiated Coverage||Hold||GBX 4,600|
|1/23/2017||Kepler Capital Markets||Reiterated Rating||Buy||GBX 5,000|
|1/18/2017||Morgan Stanley||Set Price Target||Buy||GBX 5,600|
|1/9/2017||Bryan, Garnier & Co||Reiterated Rating||Buy||GBX 5,250|
|12/6/2016||Berenberg Bank||Reiterated Rating||Buy||GBX 5,500|
|11/16/2016||Societe Generale||Reiterated Rating||Buy||GBX 6,500|
|11/7/2016||Citigroup Inc.||Reiterated Rating||Buy|
|10/19/2016||Sanford C. Bernstein||Set Price Target||Neutral||GBX 5,333|
|6/24/2016||Independent Research GmbH||Set Price Target||Sell||GBX 3,650|
|5/10/2016||Oddo Securities||Reiterated Rating||Buy||GBX 5,400|
|4/25/2016||Barclays PLC||Reiterated Rating||Equal Weight||GBX 5,000|
|3/24/2016||Natixis||Reiterated Rating||Neutral||GBX 4,456|
|3/23/2016||Nomura||Lower Price Target||Hold||GBX 4,880 -> GBX 4,350|
|2/12/2016||Baader Bank||Reiterated Rating||Hold||GBX 4,400|
|2/4/2016||S&P Equity Research||Set Price Target||Neutral||GBX 4,500|
|2/2/2016||Handelsbanken||Reiterated Rating||Accumulate||GBX 5,220.30|
|1/28/2016||Pareto Securities||Reiterated Rating||Sell||GBX 3,855.35|
|1/27/2016||Swedbank||Reiterated Rating||Buy||GBX 5,115.47|
|1/13/2016||Nordea Equity Research||Reiterated Rating||Hold||GBX 4,698.35|
Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $3.71 EPS
Dividend History for AstraZeneca plc (LON:AZN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for AstraZeneca plc (LON:AZN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/7/2015||Marc Dunoyer||Insider||Buy||10,000||GBX 4,397||£439,700|
|4/30/2015||Ann Cairns||Insider||Buy||1,100||GBX 4,455||£49,005|
|4/29/2015||Shriti Vadera||Insider||Buy||3,500||GBX 4,563||£159,705|
|4/28/2015||Graham Chipchase||Insider||Buy||1,100||GBX 4,606||£50,666|
|4/27/2015||Bruce Burlington||Insider||Buy||600||GBX 4,662||£27,972|
Latest Headlines for AstraZeneca plc (LON:AZN)
What is AstraZeneca plc's stock symbol?
AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."
How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?
AstraZeneca plc declared a dividend on Thursday, February 2nd. Stockholders of record on Thursday, February 16th will be given a dividend of GBX 150.20 per share on Monday, March 20th. This represents a dividend yield of 3.52%. The ex-dividend date is Thursday, February 16th. This is an increase from AstraZeneca plc's previous dividend of $68.70. The official announcement can be viewed at this link.
Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?
24 analysts have issued twelve-month price objectives for AstraZeneca plc's stock. Their forecasts range from GBX 3,650 to GBX 6,500. On average, they expect AstraZeneca plc's stock price to reach GBX 4,953.82 in the next year.
When will AstraZeneca plc announce their earnings?
AstraZeneca plc is scheduled to release their next quarterly earnings announcement on Thursday, April, 27th 2017.
How do I buy AstraZeneca plc stock?
Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of AstraZeneca plc stock cost?
One share of AstraZeneca plc stock can currently be purchased for approximately GBX 4,570.